Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Hodgkin Disease 1Alveolar Childhood Rhabdomyosarcoma 1

Interventions

Rituximab 23Cyclophosphamide 17Bortezomib 15Filgrastim 14Peripheral Blood Stem Cell Transplantation 13fludarabine phosphate 10Etoposide 10Vincristine 8Radiotherapy 8Cyclosporine 8tanespimycin 7Prednisone 7alvocidib 6Vorinostat 6Ifosfamide 6Doxorubicin 6Cytarabine 6Melphalan 5Lenalidomide 5Busulfan 5temsirolimus 4sargramostim 4bryostatin 1 4Paclitaxel 4Methotrexate 4Magnetic Resonance Spectroscopy 4Interferon-alpha 4Gemcitabine 4Dexamethasone 4Carboplatin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Lymphoma, Mantle-Cell × indolepropanol phosphate × Clear all
NCT00086944 2013-01-24

Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

National Cancer Institute (NCI)

Phase 1/2 Completed
25 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡